Extended indication Extension of indication to include treatment, as monotherapy or in combination with conventional syn
Therapeutic value No estimate possible yet
Total cost 213,440.00
Registration phase Registered and reimbursed


Active substance Baricitinib
Domain Chronic immune diseases
Reason of inclusion Indication extension
Main indication Rheumatism
Extended indication Extension of indication to include treatment, as monotherapy or in combination with conventional synthetic disease modifying antirheumatic drugs (DMARDs), of active juvenile idiopathic arthritis (JIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs.
Proprietary name Olumiant
Manufacturer Eli Lilly
Portfolio holder Eli Lilly
Mechanism of action JAK tyrosine kinase inhibitor
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Intermural (MSZ)


Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date September 2022
Expected Registration October 2023
Orphan drug No
Registration phase Registered and reimbursed
Additional remarks Positieve CHMP-opinie juli 2023

Therapeutic value

Current treatment options Adalimumab, etanercept, tocilizumab, abatacept, tofacitinib.
Therapeutic value No estimate possible yet
Substantiation De fase 3 studie is gepubliceerd in de Lancet met goede resultaten. Substitutie met tofacitinib. Er is een betere toedieningsfrequentie (1 keer per dag) dan tofacitinib (2 keer per dag).
Frequency of administration 1 times a day
Dosage per administration 2-4 mg
References NCT03773978; expertopinie

Expected patient volume per year

Patient volume

10 - 30

Market share is generally not included unless otherwise stated.

References ReumaNederland(1); Expertopinie(2);
Additional remarks JIA komt bij ongeveer 4.000 kinderen in Nederland voor; 30-40 nieuwe JIA diagnoses per jaar (1). Op basis van het gebruik van tofacitinib bij deze indicatie en het aantal patiënten in deze leeftijd dat gemiddeld behandeld wordt een patiëntvolume van maximaal 25-30 patiënten verwacht (2).

Expected cost per patient per year

Cost 10,672.00
References Z-index mei 2023
Additional remarks De prijs voor een verpakking van 28 tabletten Olumiant 4mg bedraagt €820,93. 1 tablet kost €29,32. Bij een behandelduur van een jaar (13 verpakkingen) zou dat €10.672,09 bedragen.

Potential total cost per year

Total cost


This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions zie overige indicaties op de horizonscan

Other information

There is currently no futher information available.